Bojar H - Search Results

1

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.

Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H. Prisack HB, et al. Among authors: bojar h. Anticancer Res. 2005 Nov-Dec;25(6C):4615-21. Anticancer Res. 2005. PMID: 16334152 Free article.

2

Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.

Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Modlich O, et al. Among authors: bojar h. Clin Cancer Res. 2004 Oct 1;10(19):6418-31. doi: 10.1158/1078-0432.CCR-04-1031. Clin Cancer Res. 2004. PMID: 15475428

3

Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures.

Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Modlich O, et al. Among authors: bojar h. J Transl Med. 2005 Aug 9;3:32. doi: 10.1186/1479-5876-3-32. J Transl Med. 2005. PMID: 16091131 Free PMC article.

4

Breast cancer expression profiling: the impact of microarray testing on clinical decision making.

Modlich O, Prisack HB, Bojar H. Modlich O, et al. Among authors: bojar h. Expert Opin Pharmacother. 2006 Oct;7(15):2069-78. doi: 10.1517/14656566.7.15.2069. Expert Opin Pharmacother. 2006. PMID: 17020433 Review.

5

Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.

Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W. Roth SL, et al. Among authors: bojar h. Strahlenther Onkol. 2010 Jun;186(6):299-306. doi: 10.1007/s00066-010-2143-0. Epub 2010 May 21. Strahlenther Onkol. 2010. PMID: 20495968

6

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO. Modlich O, et al. Among authors: bojar h. Clin Cancer Res. 2004 May 15;10(10):3410-21. doi: 10.1158/1078-0432.CCR-03-0134. Clin Cancer Res. 2004. PMID: 15161696

7

The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall Survival.

Struse K, Audretsch W, Rezai M, Pott G, Bojar H. Struse K, et al. Among authors: bojar h. Breast J. 2000 Mar;6(2):115-125. doi: 10.1046/j.1524-4741.2000.99060.x. Breast J. 2000. PMID: 11348346

8

Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer?

Modlich O, Bojar H. Modlich O, et al. Among authors: bojar h. Nat Clin Pract Oncol. 2007 Apr;4(4):216-7. doi: 10.1038/ncponc0747. Epub 2007 Feb 6. Nat Clin Pract Oncol. 2007. PMID: 17290242 No abstract available.

9

Gene expression of circulating tumour cells in breast cancer patients.

Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H. Bölke E, et al. Among authors: bojar h. Eur J Med Res. 2009 Sep 28;14(10):426-32. doi: 10.1186/2047-783x-14-10-426. Eur J Med Res. 2009. PMID: 19748849 Free PMC article.

10

Gene expression profiling of advanced head and neck squamous cell carcinomas and two squamous cell carcinoma cell lines under radio/chemotherapy using cDNA arrays.

Hartmann KA, Modlich O, Prisack HB, Gerlach B, Bojar H. Hartmann KA, et al. Among authors: bojar h. Radiother Oncol. 2002 Jun;63(3):309-20. doi: 10.1016/s0167-8140(02)00128-7. Radiother Oncol. 2002. PMID: 12142095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

119 results

Search Page

Filters